PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with preferential activity at the MC3R and MC4R subtypes. Structurally derived from Melanotan II through metabolic modification, PT-141 has been characterized in published pharmacology research for its central melanocortin pathway activation profile and its distinct receptor subtype selectivity relative to other melanocortin agonists.
Published studies have examined PT-141’s effects on MC4R-dependent signaling cascades, hypothalamic neuropeptide expression, and autonomic nervous system parameters in experimental models. The compound’s documented melanocortin receptor pharmacology has made it a reference tool in research examining central versus peripheral melanocortin pathway activation and their respective downstream functional consequences.
Supplied as a lyophilized peptide with analytical verification of cyclic structure, sequence identity, and chromatographic purity. The cyclic conformation is essential for receptor binding activity and is confirmed through structural analytical methods.
For research and investigational use only. Not for human or animal administration.
